Literature DB >> 2012963

Increased metacarpal bone mass following 18 months of slow-acting antirheumatic drugs for rheumatoid arthritis.

A A Kalla1, O L Meyers, D Chalton, S Heath, G M Brown, P R Smith, M C Burger.   

Abstract

Osteoporosis in RA is mediated by numerous inflammatory substances. This study was undertaken to see if SAARD could modify the rate of metacarpal bone loss in RA. Combined cortical thickness (CCT) measured at the midshaft of the right second metacarpal was used to calculate bone mass (CA%) using a digitizer. Eighty-one subjects were studied, all of whom had at least three sets of hand X-rays, the last of which was approximately 18 months following initiation of SAARD therapy. There were 12 males and 69 females. The mean age at time of starting therapy was 51 (SD 12) years while the mean duration of disease at the time was 7.6 (SD 8) years. The mean time to referral for SAARD from the general clinic was 2.5 (SD 3) years. The percentage fall in bone mass prior to therapy was 2.51%/day compared to a gain of 0.6%/day after therapy (P less than 0.05). Forty-nine patients were aged over 50 years while 32 were 50 years or younger at the time of study. Comparison showed that in the pretreatment period, the rate of change in CCT and CA% was not significantly dependent age (P less than 0.1). During that therapy, the rate of change in CCT and CA% significantly different in the two age groups. Patients aged over 50 years continued to lose bone, but at a slower rate (P less than 0.05). Patients aged 50 years or less either stopped losing or gained metacarpal bone mass during the study period (P less than 0.005). The time to referral for SAARD and disease duration (comparable in the two age groups) did not have a significant effect on changes in CA% during therapy. Change in bone mass could be predicted by change in disease activity. We conclude that SAARD have a significant sparing effect on metacarpal osteoporosis in RA. This positive effect is masked by the overwhelming influence of age (and menopause) and could be missed. Metacarpal osteoporosis seems a pathophysiologically more useful measure of radiological change in RA than erosions or joint space narrowing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012963     DOI: 10.1093/rheumatology/30.2.91

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  12 in total

Review 1.  Bone mass in patients with rheumatoid arthritis.

Authors:  R F Laan; P L van Riel; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Comparison between metacarpal bone measurements by computarized radiogrammetry and total body DEXA in normal and osteoporotic women.

Authors:  H Rico; M Revilla; L F Villa; J F Martin-Santos; J L Cardenas; E Fraile
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

3.  Treatment of osteoporosis of rheumatoid arthritis.

Authors:  F P Cantatore; M Carrozzo
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

4.  Digital radiogrammetry as a new diagnostic tool for estimation of disease-related osteoporosis in rheumatoid arthritis compared with pQCT.

Authors:  J Böttcher; A Pfeil; B Heinrich; G Lehmann; A Petrovitch; A Hansch; J P Heyne; H J Mentzel; A Malich; G Hein; W A Kaiser
Journal:  Rheumatol Int       Date:  2005-03-11       Impact factor: 2.631

5.  Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis.

Authors:  G Haugeberg; M J Green; M A Quinn; H Marzo-Ortega; S Proudman; Z Karim; R J Wakefield; P G Conaghan; S Stewart; P Emery
Journal:  Ann Rheum Dis       Date:  2005-11-10       Impact factor: 19.103

6.  Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis.

Authors:  Alexander Pfeil; Julia Lippold; Thorsten Eidner; Gabriele Lehmann; Peter Oelzner; Diane M Renz; Andreas Hansch; Gunter Wolf; Gert Hein; Werner A Kaiser; Joachim Böttcher
Journal:  Rheumatol Int       Date:  2008-09-12       Impact factor: 2.631

7.  Osteoporosis in rheumatoid arthritis: effect of disease activity.

Authors:  R Celiker; Y Gökçe-Kutsal; A Cindas; M Ariyürek; N Renda; Z Koray; O Basgöze
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

Review 8.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

9.  Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients.

Authors:  A A Kalla; O L Meyers; R Laubscher
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

10.  Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.

Authors:  Pernille Bøyesen; Mari Hoff; Sigrid Odegård; Glenn Haugeberg; Silje W Syversen; Per I Gaarder; Cecilie Okkenhaug; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.